VALSARTAN & HYDROCHLOROTHIAZIDE
All strengths: General benefit; same patient cost rules
Shared coverage and patient cost rules
StatusGeneral benefit
Patient paysPatient pays: program not supplied; amount cannot be determined.
Other products in the same Health Canada class (C09DA) — coverage varies; not interchangeable
- Candesartan cilexetil + hydrochlorothiazide (Atacand Plus): general benefit
- Hydrochlorothiazide + irbesartan (Avalide): general benefit, Not a benefit
- Hydrochlorothiazide + losartan (Hyzaar): general benefit
- Hydrochlorothiazide + olmesartan medoxomil (Olmetec Plus): general benefit
- Hydrochlorothiazide + telmisartan (Micardis Plus): general benefit
- Eprosartan + hydrochlorothiazide (Teveten Plus): general benefit
1 more in the class list below
Auro-Valsartan HCT · DIN 02408112 · 80mg & 12.5mg · tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Auro-Valsartan HCT · DIN 02408112
Manufacturer: Auro Pharma Inc.; listing date 2013-08-29
Health Canada: Marketed since 2013-06-19 · brand AURO-VALSARTAN HCT · ATC C09DA03 VALSARTAN AND DIURETICS, C09DA03 VALSARTAN AND DIURETICS · form Tablet · route Oral · ingredients VALSARTAN 80 MG, HYDROCHLOROTHIAZIDE 12.5 MG · company Auro pharma inc · schedule Prescription
Auro-Valsartan HCT: Formulary list price $0.2213/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.2213 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89280 · Verify on the e-Formulary ↗ (DIN 02408112)
Source record
DIN 02408112: Auro-Valsartan HCT
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800244; group id 358; item number 0832; lccId None; manufacturer id AUR
Source form: Tab; strength: 80mg & 12.5mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2213; ministry $0.2213
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02408112
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89280
Interchangeable products
Apo-Valsartan/HCTZ · DIN 02382547 · $0.2213
Diovan-HCT · DIN 02241900 · $0.2213
Sandoz Valsartan HCT · DIN 02356694 · $0.2213
Teva-Valsartan/HCTZ · DIN 02356996 · $0.2213
Valsartan HCT · DIN 02367009 · $0.2213
Valsartan HCT · DIN 02384736 · $0.2213
Shortage status: active shortage (reported 2024-08-26, last updated 2024-08-27) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02408112
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Diovan-HCT · DIN 02241900 · 80mg & 12.5mg · tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Diovan-HCT · DIN 02241900
Manufacturer: Novartis Pharma Canada Inc.; listing date 2001-03-07
Health Canada: Marketed since 2000-05-10 · brand DIOVAN-HCT · ATC C09DA03 VALSARTAN AND DIURETICS, C09DA03 VALSARTAN AND DIURETICS · form Tablet · route Oral · ingredients HYDROCHLOROTHIAZIDE 12.5 MG, VALSARTAN 80 MG · company Novartis pharmaceuticals canada inc · schedule Prescription
Ministry pays: $0.2213 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=65570 · Verify on the e-Formulary ↗ (DIN 02241900)
Source record
DIN 02241900: Diovan-HCT
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800244; group id 358; item number 0832; lccId None; manufacturer id NOV
Source form: Tab; strength: 80mg & 12.5mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $1.5441; ministry $0.2213
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02241900
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=65570
Interchangeable products
Apo-Valsartan/HCTZ · DIN 02382547 · $0.2213
Auro-Valsartan HCT · DIN 02408112 · $0.2213
Sandoz Valsartan HCT · DIN 02356694 · $0.2213
Teva-Valsartan/HCTZ · DIN 02356996 · $0.2213
Valsartan HCT · DIN 02367009 · $0.2213
Valsartan HCT · DIN 02384736 · $0.2213
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02241900
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Sandoz Valsartan HCT · DIN 02356694 · 80mg & 12.5mg · tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Sandoz Valsartan HCT · DIN 02356694
Manufacturer: Sandoz Canada Inc.; listing date 2011-06-08
Health Canada: Marketed since 2016-05-27 · brand SANDOZ VALSARTAN HCT · ATC C09DA03 VALSARTAN AND DIURETICS, C09DA03 VALSARTAN AND DIURETICS · form Tablet · route Oral · ingredients HYDROCHLOROTHIAZIDE 12.5 MG, VALSARTAN 80 MG · company Sandoz canada incorporated · schedule Prescription
Sandoz Valsartan HCT: Formulary list price $0.2213/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.2213 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84182 · Verify on the e-Formulary ↗ (DIN 02356694)
Source record
DIN 02356694: Sandoz Valsartan HCT
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800244; group id 358; item number 0832; lccId None; manufacturer id SDZ
Source form: Tab; strength: 80mg & 12.5mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2213; ministry $0.2213
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02356694
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84182
Interchangeable products
Apo-Valsartan/HCTZ · DIN 02382547 · $0.2213
Auro-Valsartan HCT · DIN 02408112 · $0.2213
Diovan-HCT · DIN 02241900 · $0.2213
Teva-Valsartan/HCTZ · DIN 02356996 · $0.2213
Valsartan HCT · DIN 02367009 · $0.2213
Valsartan HCT · DIN 02384736 · $0.2213
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02356694
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Teva-Valsartan/HCTZ · DIN 02356996 · 80mg & 12.5mg · tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Teva-Valsartan/HCTZ · DIN 02356996
Manufacturer: Teva Canada Limited; listing date 2011-06-08
Health Canada: Marketed since 2011-02-16 · brand TEVA-VALSARTAN/HCTZ · ATC C09DA03 VALSARTAN AND DIURETICS, C09DA03 VALSARTAN AND DIURETICS · form Tablet · route Oral · ingredients VALSARTAN 80 MG, HYDROCHLOROTHIAZIDE 12.5 MG · company Teva canada limited · schedule Prescription
Teva-Valsartan/HCTZ: Formulary list price $0.2213/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.2213 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84210 · Verify on the e-Formulary ↗ (DIN 02356996)
Source record
DIN 02356996: Teva-Valsartan/HCTZ
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800244; group id 358; item number 0832; lccId None; manufacturer id TEV
Source form: Tab; strength: 80mg & 12.5mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2213; ministry $0.2213
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02356996
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84210
Interchangeable products
Apo-Valsartan/HCTZ · DIN 02382547 · $0.2213
Auro-Valsartan HCT · DIN 02408112 · $0.2213
Diovan-HCT · DIN 02241900 · $0.2213
Sandoz Valsartan HCT · DIN 02356694 · $0.2213
Valsartan HCT · DIN 02367009 · $0.2213
Valsartan HCT · DIN 02384736 · $0.2213
Shortage status: discontinued (2025-04-07, reported by TEVA CANADA LIMITED); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02356996
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Valsartan HCT · DIN 02367009 · 80mg & 12.5mg · tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Valsartan HCT · DIN 02367009
Manufacturer: Sanis Health Inc.; listing date 2020-10-30
Health Canada: Marketed since 2022-02-18 · brand VALSARTAN HCT · ATC C09DA03 VALSARTAN AND DIURETICS, C09DA03 VALSARTAN AND DIURETICS · form Tablet · route Oral · ingredients VALSARTAN 80 MG, HYDROCHLOROTHIAZIDE 12.5 MG · company Sanis health inc · schedule Prescription
Valsartan HCT: Formulary list price $0.2213/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.2213 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85182 · Verify on the e-Formulary ↗ (DIN 02367009)
Source record
DIN 02367009: Valsartan HCT
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800244; group id 358; item number 0832; lccId None; manufacturer id SAI
Source form: Tab; strength: 80mg & 12.5mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2213; ministry $0.2213
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02367009
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85182
Interchangeable products
Apo-Valsartan/HCTZ · DIN 02382547 · $0.2213
Auro-Valsartan HCT · DIN 02408112 · $0.2213
Diovan-HCT · DIN 02241900 · $0.2213
Sandoz Valsartan HCT · DIN 02356694 · $0.2213
Teva-Valsartan/HCTZ · DIN 02356996 · $0.2213
Valsartan HCT · DIN 02384736 · $0.2213
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02367009
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Valsartan HCT · DIN 02384736 · 80mg & 12.5mg · tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Valsartan HCT · DIN 02384736
Manufacturer: Sivem Pharmaceuticals ULC; listing date 2020-07-31
Health Canada: Marketed since 2012-06-10 · brand VALSARTAN HCT · ATC C09DA03 VALSARTAN AND DIURETICS, C09DA03 VALSARTAN AND DIURETICS · form Tablet · route Oral · ingredients HYDROCHLOROTHIAZIDE 12.5 MG, VALSARTAN 80 MG · company Sivem pharmaceuticals ulc · schedule Prescription
Valsartan HCT: Formulary list price $0.2213/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.2213 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87042 · Verify on the e-Formulary ↗ (DIN 02384736)
Source record
DIN 02384736: Valsartan HCT
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800244; group id 358; item number 0832; lccId None; manufacturer id SIV
Source form: Tab; strength: 80mg & 12.5mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2213; ministry $0.2213
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02384736
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87042
Interchangeable products
Apo-Valsartan/HCTZ · DIN 02382547 · $0.2213
Auro-Valsartan HCT · DIN 02408112 · $0.2213
Diovan-HCT · DIN 02241900 · $0.2213
Sandoz Valsartan HCT · DIN 02356694 · $0.2213
Teva-Valsartan/HCTZ · DIN 02356996 · $0.2213
Valsartan HCT · DIN 02367009 · $0.2213
Shortage status: resolved shortage (ended 2020-02-23); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02384736
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Auro-Valsartan HCT · DIN 02408120 · 160mg & 12.5mg · tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Auro-Valsartan HCT · DIN 02408120
Manufacturer: Auro Pharma Inc.; listing date 2013-08-29
Health Canada: Marketed since 2013-06-19 · brand AURO-VALSARTAN HCT · ATC C09DA03 VALSARTAN AND DIURETICS, C09DA03 VALSARTAN AND DIURETICS · form Tablet · route Oral · ingredients HYDROCHLOROTHIAZIDE 12.5 MG, VALSARTAN 160 MG · company Auro pharma inc · schedule Prescription
Auro-Valsartan HCT: Formulary list price $0.2240/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.2240 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89287 · Verify on the e-Formulary ↗ (DIN 02408120)
Source record
DIN 02408120: Auro-Valsartan HCT
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800245; group id 358; item number 0833; lccId None; manufacturer id AUR
Source form: Tab; strength: 160mg & 12.5mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2240; ministry $0.2240
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02408120
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89287
Interchangeable products
Apo-Valsartan/HCTZ · DIN 02382555 · $0.2240
Diovan-HCT · DIN 02241901 · $0.2240
Sandoz Valsartan HCT · DIN 02356708 · $0.2240
Teva-Valsartan/HCTZ · DIN 02357003 · $0.2240
Valsartan HCT · DIN 02367017 · $0.2240
Valsartan HCT · DIN 02384744 · $0.2240
Shortage status: active shortage (reported 2024-12-05, estimated to end 2026-07-31, last updated 2026-08-04); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02408120
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Auro-Valsartan HCT · DIN 02408139 · 160mg & 25mg · tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Auro-Valsartan HCT · DIN 02408139
Manufacturer: Auro Pharma Inc.; listing date 2013-08-29
Health Canada: Marketed since 2013-06-19 · brand AURO-VALSARTAN HCT · ATC C09DA03 VALSARTAN AND DIURETICS, C09DA03 VALSARTAN AND DIURETICS · form Tablet · route Oral · ingredients VALSARTAN 160 MG, HYDROCHLOROTHIAZIDE 25 MG · company Auro pharma inc · schedule Prescription
Auro-Valsartan HCT: Formulary list price $0.2238/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.2238 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89288 · Verify on the e-Formulary ↗ (DIN 02408139)
Source record
DIN 02408139: Auro-Valsartan HCT
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800253; group id 358; item number 0834; lccId None; manufacturer id AUR
Source form: Tab; strength: 160mg & 25mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2238; ministry $0.2238
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02408139
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89288
Interchangeable products
Apo-Valsartan/HCTZ · DIN 02382563 · $0.2238
Diovan-HCT · DIN 02246955 · $0.2238
Sandoz Valsartan HCT · DIN 02356716 · $0.2238
Teva-Valsartan/HCTZ · DIN 02357011 · $0.2238
Valsartan HCT · DIN 02367025 · $0.2238
Valsartan HCT · DIN 02384752 · $0.2238
Shortage status: active shortage (reported 2024-08-26, last updated 2024-08-27) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02408139
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Diovan-HCT · DIN 02241901 · 160mg & 12.5mg · tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Diovan-HCT · DIN 02241901
Manufacturer: Novartis Pharma Canada Inc.; listing date 2001-03-07
Health Canada: Marketed since 2000-05-10 · brand DIOVAN-HCT · ATC C09DA03 VALSARTAN AND DIURETICS, C09DA03 VALSARTAN AND DIURETICS · form Tablet · route Oral · ingredients VALSARTAN 160 MG, HYDROCHLOROTHIAZIDE 12.5 MG · company Novartis pharmaceuticals canada inc · schedule Prescription
Ministry pays: $0.2240 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=65571 · Verify on the e-Formulary ↗ (DIN 02241901)
Source record
DIN 02241901: Diovan-HCT
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800245; group id 358; item number 0833; lccId None; manufacturer id NOV
Source form: Tab; strength: 160mg & 12.5mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $1.5616; ministry $0.2240
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02241901
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=65571
Interchangeable products
Apo-Valsartan/HCTZ · DIN 02382555 · $0.2240
Auro-Valsartan HCT · DIN 02408120 · $0.2240
Sandoz Valsartan HCT · DIN 02356708 · $0.2240
Teva-Valsartan/HCTZ · DIN 02357003 · $0.2240
Valsartan HCT · DIN 02367017 · $0.2240
Valsartan HCT · DIN 02384744 · $0.2240
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02241901
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Diovan-HCT · DIN 02246955 · 160mg & 25mg · tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Diovan-HCT · DIN 02246955
Manufacturer: Novartis Pharma Canada Inc.; listing date 2003-09-04
Health Canada: Marketed since 2003-01-24 · brand DIOVAN-HCT · ATC C09DA03 VALSARTAN AND DIURETICS, C09DA03 VALSARTAN AND DIURETICS · form Tablet · route Oral · ingredients VALSARTAN 160 MG, HYDROCHLOROTHIAZIDE 25 MG · company Novartis pharmaceuticals canada inc · schedule Prescription
Ministry pays: $0.2238 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=71182 · Verify on the e-Formulary ↗ (DIN 02246955)
Source record
DIN 02246955: Diovan-HCT
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800253; group id 358; item number 0834; lccId None; manufacturer id NOV
Source form: Tab; strength: 160mg & 25mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $1.5616; ministry $0.2238
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02246955
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=71182
Interchangeable products
Apo-Valsartan/HCTZ · DIN 02382563 · $0.2238
Auro-Valsartan HCT · DIN 02408139 · $0.2238
Sandoz Valsartan HCT · DIN 02356716 · $0.2238
Teva-Valsartan/HCTZ · DIN 02357011 · $0.2238
Valsartan HCT · DIN 02367025 · $0.2238
Valsartan HCT · DIN 02384752 · $0.2238
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02246955
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Sandoz Valsartan HCT · DIN 02356708 · 160mg & 12.5mg · tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Sandoz Valsartan HCT · DIN 02356708
Manufacturer: Sandoz Canada Inc.; listing date 2011-06-08
Health Canada: Marketed since 2016-05-27 · brand SANDOZ VALSARTAN HCT · ATC C09DA03 VALSARTAN AND DIURETICS, C09DA03 VALSARTAN AND DIURETICS · form Tablet · route Oral · ingredients VALSARTAN 160 MG, HYDROCHLOROTHIAZIDE 12.5 MG · company Sandoz canada incorporated · schedule Prescription
Sandoz Valsartan HCT: Formulary list price $0.2240/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.2240 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84183 · Verify on the e-Formulary ↗ (DIN 02356708)
Source record
DIN 02356708: Sandoz Valsartan HCT
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800245; group id 358; item number 0833; lccId None; manufacturer id SDZ
Source form: Tab; strength: 160mg & 12.5mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2240; ministry $0.2240
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02356708
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84183
Interchangeable products
Apo-Valsartan/HCTZ · DIN 02382555 · $0.2240
Auro-Valsartan HCT · DIN 02408120 · $0.2240
Diovan-HCT · DIN 02241901 · $0.2240
Teva-Valsartan/HCTZ · DIN 02357003 · $0.2240
Valsartan HCT · DIN 02367017 · $0.2240
Valsartan HCT · DIN 02384744 · $0.2240
Shortage status: resolved shortage (ended 2022-10-19); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02356708
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Sandoz Valsartan HCT · DIN 02356716 · 160mg & 25mg · tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Sandoz Valsartan HCT · DIN 02356716
Manufacturer: Sandoz Canada Inc.; listing date 2011-06-08
Health Canada: Marketed since 2016-05-27 · brand SANDOZ VALSARTAN HCT · ATC C09DA03 VALSARTAN AND DIURETICS, C09DA03 VALSARTAN AND DIURETICS · form Tablet · route Oral · ingredients HYDROCHLOROTHIAZIDE 25 MG, VALSARTAN 160 MG · company Sandoz canada incorporated · schedule Prescription
Sandoz Valsartan HCT: Formulary list price $0.2238/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.2238 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84184 · Verify on the e-Formulary ↗ (DIN 02356716)
Source record
DIN 02356716: Sandoz Valsartan HCT
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800253; group id 358; item number 0834; lccId None; manufacturer id SDZ
Source form: Tab; strength: 160mg & 25mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2238; ministry $0.2238
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02356716
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84184
Interchangeable products
Apo-Valsartan/HCTZ · DIN 02382563 · $0.2238
Auro-Valsartan HCT · DIN 02408139 · $0.2238
Diovan-HCT · DIN 02246955 · $0.2238
Teva-Valsartan/HCTZ · DIN 02357011 · $0.2238
Valsartan HCT · DIN 02367025 · $0.2238
Valsartan HCT · DIN 02384752 · $0.2238
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02356716
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Teva-Valsartan/HCTZ · DIN 02357003 · 160mg & 12.5mg · tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Teva-Valsartan/HCTZ · DIN 02357003
Manufacturer: Teva Canada Limited; listing date 2011-06-08
Health Canada: Marketed since 2011-02-16 · brand TEVA-VALSARTAN/HCTZ · ATC C09DA03 VALSARTAN AND DIURETICS, C09DA03 VALSARTAN AND DIURETICS · form Tablet · route Oral · ingredients HYDROCHLOROTHIAZIDE 12.5 MG, VALSARTAN 160 MG · company Teva canada limited · schedule Prescription
Teva-Valsartan/HCTZ: Formulary list price $0.2240/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.2240 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84211 · Verify on the e-Formulary ↗ (DIN 02357003)
Source record
DIN 02357003: Teva-Valsartan/HCTZ
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800245; group id 358; item number 0833; lccId None; manufacturer id TEV
Source form: Tab; strength: 160mg & 12.5mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2240; ministry $0.2240
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02357003
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84211
Interchangeable products
Apo-Valsartan/HCTZ · DIN 02382555 · $0.2240
Auro-Valsartan HCT · DIN 02408120 · $0.2240
Diovan-HCT · DIN 02241901 · $0.2240
Sandoz Valsartan HCT · DIN 02356708 · $0.2240
Valsartan HCT · DIN 02367017 · $0.2240
Valsartan HCT · DIN 02384744 · $0.2240
Shortage status: discontinued (2025-04-07, reported by TEVA CANADA LIMITED); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02357003
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Teva-Valsartan/HCTZ · DIN 02357011 · 160mg & 25mg · tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Teva-Valsartan/HCTZ · DIN 02357011
Manufacturer: Teva Canada Limited; listing date 2011-06-08
Health Canada: Marketed since 2011-02-16 · brand TEVA-VALSARTAN/HCTZ · ATC C09DA03 VALSARTAN AND DIURETICS, C09DA03 VALSARTAN AND DIURETICS · form Tablet · route Oral · ingredients VALSARTAN 160 MG, HYDROCHLOROTHIAZIDE 25 MG · company Teva canada limited · schedule Prescription
Teva-Valsartan/HCTZ: Formulary list price $0.2238/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.2238 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84212 · Verify on the e-Formulary ↗ (DIN 02357011)
Source record
DIN 02357011: Teva-Valsartan/HCTZ
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800253; group id 358; item number 0834; lccId None; manufacturer id TEV
Source form: Tab; strength: 160mg & 25mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2238; ministry $0.2238
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02357011
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84212
Interchangeable products
Apo-Valsartan/HCTZ · DIN 02382563 · $0.2238
Auro-Valsartan HCT · DIN 02408139 · $0.2238
Diovan-HCT · DIN 02246955 · $0.2238
Sandoz Valsartan HCT · DIN 02356716 · $0.2238
Valsartan HCT · DIN 02367025 · $0.2238
Valsartan HCT · DIN 02384752 · $0.2238
Shortage status: discontinued (2025-04-07, reported by TEVA CANADA LIMITED); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02357011
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Valsartan HCT · DIN 02367017 · 160mg & 12.5mg · tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Valsartan HCT · DIN 02367017
Manufacturer: Sanis Health Inc.; listing date 2020-10-30
Health Canada: Marketed since 2022-02-18 · brand VALSARTAN HCT · ATC C09DA03 VALSARTAN AND DIURETICS, C09DA03 VALSARTAN AND DIURETICS · form Tablet · route Oral · ingredients HYDROCHLOROTHIAZIDE 12.5 MG, VALSARTAN 160 MG · company Sanis health inc · schedule Prescription
Valsartan HCT: Formulary list price $0.2240/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.2240 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85183 · Verify on the e-Formulary ↗ (DIN 02367017)
Source record
DIN 02367017: Valsartan HCT
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800245; group id 358; item number 0833; lccId None; manufacturer id SAI
Source form: Tab; strength: 160mg & 12.5mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2240; ministry $0.2240
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02367017
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85183
Interchangeable products
Apo-Valsartan/HCTZ · DIN 02382555 · $0.2240
Auro-Valsartan HCT · DIN 02408120 · $0.2240
Diovan-HCT · DIN 02241901 · $0.2240
Sandoz Valsartan HCT · DIN 02356708 · $0.2240
Teva-Valsartan/HCTZ · DIN 02357003 · $0.2240
Valsartan HCT · DIN 02384744 · $0.2240
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02367017
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Valsartan HCT · DIN 02367025 · 160mg & 25mg · tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Valsartan HCT · DIN 02367025
Manufacturer: Sanis Health Inc.; listing date 2020-10-30
Health Canada: Marketed since 2022-02-18 · brand VALSARTAN HCT · ATC C09DA03 VALSARTAN AND DIURETICS, C09DA03 VALSARTAN AND DIURETICS · form Tablet · route Oral · ingredients VALSARTAN 160 MG, HYDROCHLOROTHIAZIDE 25 MG · company Sanis health inc · schedule Prescription
Valsartan HCT: Formulary list price $0.2238/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.2238 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85184 · Verify on the e-Formulary ↗ (DIN 02367025)
Source record
DIN 02367025: Valsartan HCT
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800253; group id 358; item number 0834; lccId None; manufacturer id SAI
Source form: Tab; strength: 160mg & 25mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2238; ministry $0.2238
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02367025
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85184
Interchangeable products
Apo-Valsartan/HCTZ · DIN 02382563 · $0.2238
Auro-Valsartan HCT · DIN 02408139 · $0.2238
Diovan-HCT · DIN 02246955 · $0.2238
Sandoz Valsartan HCT · DIN 02356716 · $0.2238
Teva-Valsartan/HCTZ · DIN 02357011 · $0.2238
Valsartan HCT · DIN 02384752 · $0.2238
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02367025
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Valsartan HCT · DIN 02384744 · 160mg & 12.5mg · tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Valsartan HCT · DIN 02384744
Manufacturer: Sivem Pharmaceuticals ULC; listing date 2020-07-31
Health Canada: Marketed since 2012-06-10 · brand VALSARTAN HCT · ATC C09DA03 VALSARTAN AND DIURETICS, C09DA03 VALSARTAN AND DIURETICS · form Tablet · route Oral · ingredients HYDROCHLOROTHIAZIDE 12.5 MG, VALSARTAN 160 MG · company Sivem pharmaceuticals ulc · schedule Prescription
Valsartan HCT: Formulary list price $0.2240/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.2240 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87043 · Verify on the e-Formulary ↗ (DIN 02384744)
Source record
DIN 02384744: Valsartan HCT
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800245; group id 358; item number 0833; lccId None; manufacturer id SIV
Source form: Tab; strength: 160mg & 12.5mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2240; ministry $0.2240
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02384744
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87043
Interchangeable products
Apo-Valsartan/HCTZ · DIN 02382555 · $0.2240
Auro-Valsartan HCT · DIN 02408120 · $0.2240
Diovan-HCT · DIN 02241901 · $0.2240
Sandoz Valsartan HCT · DIN 02356708 · $0.2240
Teva-Valsartan/HCTZ · DIN 02357003 · $0.2240
Valsartan HCT · DIN 02367017 · $0.2240
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02384744
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Valsartan HCT · DIN 02384752 · 160mg & 25mg · tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Valsartan HCT · DIN 02384752
Manufacturer: Sivem Pharmaceuticals ULC; listing date 2020-07-31
Health Canada: Marketed since 2012-06-10 · brand VALSARTAN HCT · ATC C09DA03 VALSARTAN AND DIURETICS, C09DA03 VALSARTAN AND DIURETICS · form Tablet · route Oral · ingredients HYDROCHLOROTHIAZIDE 25 MG, VALSARTAN 160 MG · company Sivem pharmaceuticals ulc · schedule Prescription
Valsartan HCT: Formulary list price $0.2238/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.2238 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87044 · Verify on the e-Formulary ↗ (DIN 02384752)
Source record
DIN 02384752: Valsartan HCT
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800253; group id 358; item number 0834; lccId None; manufacturer id SIV
Source form: Tab; strength: 160mg & 25mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2238; ministry $0.2238
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02384752
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87044
Interchangeable products
Apo-Valsartan/HCTZ · DIN 02382563 · $0.2238
Auro-Valsartan HCT · DIN 02408139 · $0.2238
Diovan-HCT · DIN 02246955 · $0.2238
Sandoz Valsartan HCT · DIN 02356716 · $0.2238
Teva-Valsartan/HCTZ · DIN 02357011 · $0.2238
Valsartan HCT · DIN 02367025 · $0.2238
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02384752
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Auro-Valsartan HCT · DIN 02408147 · 320mg & 12.5mg · tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Auro-Valsartan HCT · DIN 02408147
Manufacturer: Auro Pharma Inc.; listing date 2013-08-29
Health Canada: Marketed since 2013-06-19 · brand AURO-VALSARTAN HCT · ATC C09DA03 VALSARTAN AND DIURETICS, C09DA03 VALSARTAN AND DIURETICS · form Tablet · route Oral · ingredients VALSARTAN 320 MG, HYDROCHLOROTHIAZIDE 12.5 MG · company Auro pharma inc · schedule Prescription
Auro-Valsartan HCT: Formulary list price $0.2235/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.2235 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89289 · Verify on the e-Formulary ↗ (DIN 02408147)
Source record
DIN 02408147: Auro-Valsartan HCT
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800277; group id 358; item number 0835; lccId None; manufacturer id AUR
Source form: Tab; strength: 320mg & 12.5mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2235; ministry $0.2235
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02408147
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89289
Interchangeable products
Apo-Valsartan/HCTZ · DIN 02382571 · $0.2235
Diovan-HCT · DIN 02308908 · $0.2235
Sandoz Valsartan HCT · DIN 02356724 · $0.2235
Teva-Valsartan/HCTZ · DIN 02357038 · $0.2235
Valsartan HCT · DIN 02367033 · $0.2235
Valsartan HCT · DIN 02384760 · $0.2235
Shortage status: active shortage (reported 2024-08-26, last updated 2024-08-27) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02408147
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Auro-Valsartan HCT · DIN 02408155 · 320mg & 25mg · tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Auro-Valsartan HCT · DIN 02408155
Manufacturer: Auro Pharma Inc.; listing date 2013-08-29
Health Canada: Marketed since 2013-06-19 · brand AURO-VALSARTAN HCT · ATC C09DA03 VALSARTAN AND DIURETICS, C09DA03 VALSARTAN AND DIURETICS · form Tablet · route Oral · ingredients VALSARTAN 320 MG, HYDROCHLOROTHIAZIDE 25 MG · company Auro pharma inc · schedule Prescription
Auro-Valsartan HCT: Formulary list price $0.2231/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.2231 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89290 · Verify on the e-Formulary ↗ (DIN 02408155)
Source record
DIN 02408155: Auro-Valsartan HCT
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800278; group id 358; item number 0836; lccId None; manufacturer id AUR
Source form: Tab; strength: 320mg & 25mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2231; ministry $0.2231
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02408155
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89290
Interchangeable products
Apo-Valsartan/HCTZ · DIN 02382598 · $0.2231
Diovan-HCT · DIN 02308916 · $0.2231
Sandoz Valsartan HCT · DIN 02356732 · $0.2231
Teva-Valsartan/HCTZ · DIN 02357046 · $0.2231
Valsartan HCT · DIN 02367041 · $0.2231
Shortage status: active shortage (reported 2024-08-26, last updated 2024-08-27) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02408155
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Diovan-HCT · DIN 02308908 · 320mg & 12.5mg · tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Diovan-HCT · DIN 02308908
Manufacturer: Novartis Pharma Canada Inc.; listing date 2009-03-02
Health Canada: Marketed since 2008-05-12 · brand DIOVAN-HCT · ATC C09DA03 VALSARTAN AND DIURETICS, C09DA03 VALSARTAN AND DIURETICS · form Tablet · route Oral · ingredients VALSARTAN 320 MG, HYDROCHLOROTHIAZIDE 12.5 MG · company Novartis pharmaceuticals canada inc · schedule Prescription
Ministry pays: $0.2235 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=79451 · Verify on the e-Formulary ↗ (DIN 02308908)
Source record
DIN 02308908: Diovan-HCT
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800277; group id 358; item number 0835; lccId None; manufacturer id NOV
Source form: Tab; strength: 320mg & 12.5mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $1.5580; ministry $0.2235
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02308908
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=79451
Interchangeable products
Apo-Valsartan/HCTZ · DIN 02382571 · $0.2235
Auro-Valsartan HCT · DIN 02408147 · $0.2235
Sandoz Valsartan HCT · DIN 02356724 · $0.2235
Teva-Valsartan/HCTZ · DIN 02357038 · $0.2235
Valsartan HCT · DIN 02367033 · $0.2235
Valsartan HCT · DIN 02384760 · $0.2235
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02308908
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Diovan-HCT · DIN 02308916 · 320mg & 25mg · tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Diovan-HCT · DIN 02308916
Manufacturer: Novartis Pharma Canada Inc.; listing date 2009-03-02
Health Canada: Marketed since 2008-05-12 · brand DIOVAN-HCT · ATC C09DA03 VALSARTAN AND DIURETICS, C09DA03 VALSARTAN AND DIURETICS · form Tablet · route Oral · ingredients HYDROCHLOROTHIAZIDE 25 MG, VALSARTAN 320 MG · company Novartis pharmaceuticals canada inc · schedule Prescription
Ministry pays: $0.2231 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=79452 · Verify on the e-Formulary ↗ (DIN 02308916)
Source record
DIN 02308916: Diovan-HCT
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800278; group id 358; item number 0836; lccId None; manufacturer id NOV
Source form: Tab; strength: 320mg & 25mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $1.5555; ministry $0.2231
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02308916
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=79452
Interchangeable products
Apo-Valsartan/HCTZ · DIN 02382598 · $0.2231
Auro-Valsartan HCT · DIN 02408155 · $0.2231
Sandoz Valsartan HCT · DIN 02356732 · $0.2231
Teva-Valsartan/HCTZ · DIN 02357046 · $0.2231
Valsartan HCT · DIN 02367041 · $0.2231
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02308916
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Sandoz Valsartan HCT · DIN 02356724 · 320mg & 12.5mg · tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Sandoz Valsartan HCT · DIN 02356724
Manufacturer: Sandoz Canada Inc.; listing date 2011-06-08
Health Canada: Marketed since 2016-05-27 · brand SANDOZ VALSARTAN HCT · ATC C09DA03 VALSARTAN AND DIURETICS, C09DA03 VALSARTAN AND DIURETICS · form Tablet · route Oral · ingredients VALSARTAN 320 MG, HYDROCHLOROTHIAZIDE 12.5 MG · company Sandoz canada incorporated · schedule Prescription
Sandoz Valsartan HCT: Formulary list price $0.2235/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.2235 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84185 · Verify on the e-Formulary ↗ (DIN 02356724)
Source record
DIN 02356724: Sandoz Valsartan HCT
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800277; group id 358; item number 0835; lccId None; manufacturer id SDZ
Source form: Tab; strength: 320mg & 12.5mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2235; ministry $0.2235
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02356724
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84185
Interchangeable products
Apo-Valsartan/HCTZ · DIN 02382571 · $0.2235
Auro-Valsartan HCT · DIN 02408147 · $0.2235
Diovan-HCT · DIN 02308908 · $0.2235
Teva-Valsartan/HCTZ · DIN 02357038 · $0.2235
Valsartan HCT · DIN 02367033 · $0.2235
Valsartan HCT · DIN 02384760 · $0.2235
Shortage status: resolved shortage (ended 2022-11-28); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02356724
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Sandoz Valsartan HCT · DIN 02356732 · 320mg & 25mg · tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Sandoz Valsartan HCT · DIN 02356732
Manufacturer: Sandoz Canada Inc.; listing date 2011-06-08
Health Canada: Marketed since 2016-05-27 · brand SANDOZ VALSARTAN HCT · ATC C09DA03 VALSARTAN AND DIURETICS, C09DA03 VALSARTAN AND DIURETICS · form Tablet · route Oral · ingredients HYDROCHLOROTHIAZIDE 25 MG, VALSARTAN 320 MG · company Sandoz canada incorporated · schedule Prescription
Sandoz Valsartan HCT: Formulary list price $0.2231/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.2231 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84186 · Verify on the e-Formulary ↗ (DIN 02356732)
Source record
DIN 02356732: Sandoz Valsartan HCT
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800278; group id 358; item number 0836; lccId None; manufacturer id SDZ
Source form: Tab; strength: 320mg & 25mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2231; ministry $0.2231
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02356732
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84186
Interchangeable products
Apo-Valsartan/HCTZ · DIN 02382598 · $0.2231
Auro-Valsartan HCT · DIN 02408155 · $0.2231
Diovan-HCT · DIN 02308916 · $0.2231
Teva-Valsartan/HCTZ · DIN 02357046 · $0.2231
Valsartan HCT · DIN 02367041 · $0.2231
Shortage status: resolved shortage (ended 2026-08-24); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02356732
Shortage record checked 2026-09-13T08:10:21.292534+00:00